Cancer and the MMP/TIMP Panel
A matched antibody panel for studying matrix metalloproteinases and their inhibitors in tumor invasion, ECM remodeling, and metastasis.
Matrix metalloproteinases (MMPs) are a family of zinc-dependent endopeptidases that collectively degrade nearly every component of the extracellular matrix (ECM). In cancer, dysregulated MMP activity drives invasion, intravasation, and metastatic colonization by clearing physical barriers and releasing matrix-sequestered growth factors. The 23 human MMPs—alongside their endogenous inhibitors (TIMPs) and related ADAM/ADAMTS proteases—form a tightly regulated proteolytic network that shapes the tumor microenvironment. Understanding which MMPs are active, in what form, and how TIMPs modulate them is central to invasion biology.
The MMP Family: Secreted vs Membrane-Type Architecture
MMPs share a conserved domain structure: a pro-domain that maintains latency, a catalytic domain with the zinc-binding motif, and in most cases a hemopexin domain that confers substrate specificity. Based on substrate preference and structural features, MMPs are grouped into collagenases (MMP-1, -8, -13), gelatinases (MMP-2, -9), stromelysins (MMP-3, -10), matrilysins (MMP-7, -26), and membrane-type MMPs (MT-MMPs). The MT-MMPs—MMP-14, MMP-15, MMP-16, MMP-17, MMP-24, and MMP-25—are anchored to the plasma membrane via a transmembrane domain (MMP-14, -15, -16, -24) or a glycosylphosphatidylinositol (GPI) linkage (MMP-17, -25). This membrane tethering concentrates proteolytic activity at the cell surface, particularly at invadopodia, the actin-rich protrusions that penetrate basement membrane and stroma.
Secreted MMPs diffuse away from the cell and act in the pericellular space, whereas MT-MMPs provide spatially restricted, directional proteolysis. MT-MMPs also activate pro-forms of secreted MMPs: MMP-14 is the principal activator of pro-MMP-2, forming a trimolecular complex with TIMP-2 on the cell surface. This distinction has profound implications for experimental design—measuring soluble MMP-2 in conditioned medium may miss the functionally relevant, membrane-localized pool.
MMP-9 and MMP-2 (the Gelatinases): The Most-Studied Cancer Targets
What are MMPs and why are they important in cancer?
Matrix metalloproteinases (MMPs) are a family of proteinases that degrade extracellular matrix components, facilitating tumor cell invasion through basement membranes and stromal connective tissue. Elevated MMP expression correlates with metastatic potential across multiple cancer types. MMPs also cleave cell-surface receptors, release sequestered growth factors like VEGF and TGF-β, and modulate immune cell infiltration. Because they operate at the interface between tumor cells and stroma, MMPs are attractive therapeutic targets and biomarkers of invasion. The gelatinases MMP-2 and MMP-9 are the most extensively studied due to their ability to degrade type IV collagen, the principal component of basement membranes.
What's the difference between MMP-9 and MMP-2?
MMP-9 (gelatinase B) and MMP-2 (gelatinase A) both cleave gelatin and type IV collagen but differ in regulation and cellular source. MMP-9 is typically expressed by inflammatory cells—neutrophils, macrophages—and is strongly inducible by cytokines and growth factors. MMP-2 is more constitutively expressed by stromal fibroblasts and tumor cells and is activated on the cell surface by MT1-MMP in a TIMP-2-dependent mechanism. In breast cancer models, MMP-9 often marks inflammatory or necrotic regions, whereas MMP-2 correlates with leading-edge invasion. Both gelatinases are therapeutic targets; recent drug repurposing screens identified paroxetine as an inhibitor of MMP-2/9 and HSP27 crosstalk in glioblastoma.1
Expression profiling across breast cancer subtypes reveals coordinated regulation of the MMP-TIMP-miRNA axis, with MMP-2 and MMP-9 upregulated in triple-negative and HER2-positive lines relative to luminal A.2 In fibrosarcoma, nafamostat mesylate suppresses both MMP-2 and MMP-9 mRNA and protein, correlating with reduced invasion.5 For laboratories dissecting gelatinase contributions, TPB offers validated Anti-MMP-2 and Anti-MMP-9 rabbit polyclonal antibodies, each raised against recombinant catalytic domain fragments and validated for Western blot detection of both pro- and active forms.
Membrane-Type MMPs (MT-MMPs / MMP-14, 15, 16, 17, 24, 25): Invadopodia Biology
What is MT1-MMP and why is it important for tumor invasion?
MT1-MMP (MMP-14) is a membrane-anchored metalloproteinase that localizes to invadopodia, the actin-rich protrusions tumor cells use to breach the basement membrane. Unlike secreted MMPs, MT1-MMP concentrates proteolytic activity precisely at sites of ECM contact, enabling focused degradation of collagen I and IV. MT1-MMP also activates pro-MMP-2 at the cell surface, amplifying gelatinase activity in the pericellular space. Genetic knockout or antibody blockade of MT1-MMP abolishes invasive capacity in three-dimensional collagen matrices, underscoring its non-redundant role. MT1-MMP expression correlates with poor prognosis in carcinomas of breast, colon, and brain, and is a key target for mechanistic studies of invasion.
Beyond MMP-14, the other MT-MMPs each exhibit distinct expression patterns and substrates. MMP-15 and MMP-16 share transmembrane topology with MMP-14 and activate pro-MMP-2, though with lower efficiency. MMP-17, a GPI-anchored protease, is expressed on leukocytes and may regulate shedding of adhesion molecules. MMP-24 (MT5-MMP) is brain-enriched, implicated in glioma invasion; TPB offers both human and mouse isoforms. MMP-25 (MT6-MMP) cleaves pro-MMP-2 and gelatin and is upregulated in some leukemias. For invadopodia studies, a panel including Anti-MMP-14, Anti-MMP-2, and Anti-TIMP-2 captures the trimolecular activation complex and its downstream effector.
MMP-1, MMP-3, MMP-13: The Cartilage Triad in Cancer Context
MMP-1 (interstitial collagenase), MMP-3 (stromelysin-1), and MMP-13 (collagenase-3) were originally characterized in joint cartilage degradation but are frequently overexpressed in carcinomas. MMP-1 cleaves fibrillar collagens I, II, and III, initiating the unwinding of triple-helical collagen—a rate-limiting step in stromal remodeling. In breast cancer, MMP-1 is induced by EGF and TGF-β and promotes invasion through collagen-rich stroma. MMP-13 exhibits broader collagenolytic activity and is highly expressed in squamous cell carcinomas and bone metastases, where it degrades both cartilage and bone matrix.
MMP-3 has a broad substrate range, cleaving collagens, laminin, fibronectin, and pro-TNF-α. In cardia carcinoma, MMP-3 is upregulated in tumor-associated macrophages, contributing to a pro-invasive microenvironment.7 MMP-3 also activates other pro-MMPs, including pro-MMP-1 and pro-MMP-9, positioning it as an upstream regulator of the proteolytic cascade. Esculetin, a coumarin derivative, attenuates migration in hepatocellular carcinoma by reducing MMP activity and strengthening tight junctions.6 For researchers modeling stromal invasion, TPB's Anti-MMP-1, Anti-MMP-3, and Anti-MMP-13 antibodies provide orthogonal readouts of collagenase and stromelysin activity in tumor lysates and conditioned media.
TIMPs: Endogenous Inhibitors and the MMP/TIMP Balance
How do TIMPs regulate MMP activity?
Tissue inhibitors of metalloproteinases (TIMPs) are endogenous inhibitors that bind the catalytic site of active MMPs in a 1:1 stoichiometric complex, blocking substrate access. Humans express four TIMPs (TIMP-1, -2, -3, -4), each with distinct MMP preferences and tissue distributions. TIMP-1 preferentially inhibits MMP-9, while TIMP-2 regulates MMP-2 activation by forming a cell-surface complex with pro-MMP-2 and MT1-MMP. TIMP-3 is ECM-bound and inhibits both MMPs and ADAM/ADAMTS proteases. The MMP/TIMP ratio is a critical determinant of net proteolytic activity; cancer cells often downregulate TIMPs or secrete excess MMPs, tipping the balance toward matrix degradation. Experimentally, recombinant TIMP variants block invasion and migration in glioblastoma spheroid assays, validating TIMPs as invasion suppressors.
TIMP expression varies by tumor context. In breast cancer, TIMP-1 levels correlate with poor prognosis despite its inhibitory function, possibly reflecting a compensatory response to high MMP-9 or TIMP-1's pro-survival signaling via CD63. TIMP-3 is frequently silenced by promoter methylation, removing a brake on ADAM17 (TACE) and MMP activity. Integrated profiling of the MMP-TIMP-miRNA axis reveals that miR-21 and miR-181 target TIMP-3, indirectly amplifying MMP activity.2 Taheri and colleagues demonstrated that minimally engineered TIMP variants retain MMP inhibition while reducing off-target effects, providing a roadmap for TIMP-based therapeutics.8
TPB offers antibodies to all four TIMPs: Anti-TIMP-1, Anti-TIMP-2, Anti-TIMP-3, and Anti-TIMP-4. Pairing TIMP detection with cognate MMP antibodies enables ratiometric analysis of the proteolytic balance in tumor lysates, a more informative metric than MMP abundance alone.
ADAM and ADAMTS Proteases: Additional ECM Remodelers
The ADAM (a disintegrin and metalloproteinase) and ADAMTS (ADAM with thrombospondin motifs) families share the metalloproteinase catalytic domain but differ in substrate preference and biological function. ADAMs are membrane-anchored sheddases that cleave cell-surface proteins—growth factors, cytokines, adhesion molecules—releasing soluble ectodomains. ADAM17 (TACE) cleaves pro-TNF-α, EGFR ligands, and Notch, driving inflammatory and proliferative signaling in multiple cancers. ADAM10 is the principal Notch sheddase and also cleaves E-cadherin, promoting epithelial-mesenchymal transition.
ADAMTS proteases are secreted and cleave ECM substrates: aggrecan, versican, and collagen. ADAMTS-1 cleaves versican, modulating ECM stiffness and growth factor availability. ADAMTS-4 and ADAMTS-5 are aggrecanases implicated in cartilage destruction and tumor stroma remodeling. ADAMTS-13 cleaves von Willebrand factor multimers; deficiency causes thrombotic thrombocytopenic purpura, but its role in cancer is emerging, particularly in platelet-tumor interactions during metastasis.
TPB's ADAM/ADAMTS panel includes ADAM-9, ADAM-10, ADAM-12, ADAM-15, ADAM-17, ADAM-28, and five ADAMTS members. These reagents enable mechanistic dissection of non-MMP metalloproteinase contributions to the tumor microenvironment.
Pro vs Active Form Detection: Why It Matters for Cancer Research
Most MMPs are secreted as inactive zymogens (pro-MMPs) with an N-terminal pro-domain occluding the catalytic zinc. Activation requires proteolytic removal of the pro-domain by furin, plasmin, or other MMPs—or by conformational disruption via oxidants. The ratio of pro- to active MMP reflects the cell's activation machinery and the local protease milieu. In cancer, high pro-MMP-2 without corresponding active MMP-2 may indicate insufficient MT1-MMP or TIMP-2 imbalance.
Antibodies that recognize both pro- and active forms (typically targeting the catalytic or hemopexin domain) provide total protein abundance, while activation-state-specific antibodies (e.g., neo-epitope antibodies recognizing the cleaved N-terminus) measure the functional pool. For invasion studies, measuring active MMP-2 by gelatin zymography alongside Western blot with a pan-MMP-2 antibody yields complementary data: total expression vs functional activation. Propofol was shown to suppress breast cancer invasion in three-dimensional microfluidic models by reducing MMP-2 activity without major effects on pro-MMP-2 expression, illustrating the importance of activation state.3
TPB's rabbit polyclonal antibodies typically recognize epitopes in the catalytic or hemopexin domain shared by pro- and active forms, enabling detection of both by Western blot (with size discrimination based on molecular weight). Pairing antibody-based detection with enzymatic assays (e.g., fluorogenic substrate cleavage) or zymography provides a full picture of MMP status.
Recommended Antibody Panel for Tumor Invasion Studies
A minimal MMP/TIMP panel for invasion research should cover the gelatinases, a representative MT-MMP, and at least one TIMP to assess the proteolytic balance. We recommend:
- Anti-MMP-2 and Anti-MMP-9 to capture gelatinase activity in conditioned media and lysates.
- Anti-MMP-14 to detect MT1-MMP at invadopodia and assess pro-MMP-2 activation.
- Anti-TIMP-2 to measure the endogenous regulator of the MMP-2 activation complex.
- Anti-MMP-1 or Anti-MMP-13 if modeling invasion through collagen-rich stroma or bone.
- Anti-ADAM17 if investigating growth factor shedding or inflammatory crosstalk.
For broader screens, TPB's catalog spans all 23 MMPs plus orphan and minor family members (e.g., MMP-19, MMP-28) rarely covered by commercial suppliers. Each antibody is raised in rabbit against recombinant human antigen and validated for Western blot; many show predicted cross-reactivity to mouse and rat orthologs, enabling translation to preclinical models.
TPB's MMP/TIMP/ADAM/ADAMTS Catalog
Since 1994, Triple Point Biologics has specialized in rabbit polyclonal antibodies to proteinases, inhibitors, and ECM components. Our MMP/TIMP panel includes every classical MMP, all four TIMPs, representative ADAM and ADAMTS members, and related proteases such as BMP-1, Pappalysin-1, and RECK, a membrane-anchored MMP inhibitor. Each antibody is supplied as antiserum or affinity-purified IgG, with lot-specific validation data available on request. For laboratories requiring consistent, research-grade reagents for mechanistic studies of tumor invasion, our catalog provides depth unmatched by high-throughput antibody vendors.
References
- Nandi S et al. Targeting of HSP27 and MMP-2/9 Crosstalk by High-Throughput Drug Repurposing Strategies Identifies Paroxetine as a Potential Candidate in Glioblastoma. J Med Chem 2026. PMID: 41698807.
- Lukianova N et al. Integrated expression profile of the MMP-TIMP-miRNA axis in breast cancer cell lines of different molecular subtypes. Exp Oncol 2025. PMID: 41486540.
- Wan Z et al. Propofol suppresses breast cancer invasion: An in vitro three-dimensional cell invasion model with microfluidic technology. J Appl Biomed 2025. PMID: 41403230.
- Shoari A et al. Therapeutic potential of inhibitors of gelatinases MMP-2 and MMP-9 for the treatment of breast cancer. FEBS J 2025. PMID: 41313679.
- Yildirim C. Multifaceted anticancer activity of nafamostat mesylate in human fibrosarcoma: first evidence of mitochondrial apoptosis and suppressed MMP-2/-9 mRNA expression. BMC Pharmacol Toxicol 2025. PMID: 41257996.
- Kim SO et al. Esculetin Attenuates the Migration and Invasion of Human Hepatocellular Carcinoma Cells by Attenuating Matrix Metalloproteinase Activity and Strengthening Tight Junctions. J Cancer Prev 2025. PMID: 40621158.
- Zhang Z et al. Effects of tumour-associated macrophages on cardia carcinoma progression. Eur J Med Res 2025. PMID: 40597264.
- Taheri E. Effect of TIMPs and their minimally engineered variants in blocking invasion and migration of brain cancer cells. Oncotarget 2025. PMID: 40019229.
MMP/TIMP/ADAM/ADAMTS Antibody Catalog
Gelatinases
Anti-MMP-2 Rabbit Polyclonal AntibodyGelatinase A; cleaves type IV collagen and gelatin; activated by MT1-MMP.
Anti-MMP-9 Rabbit Polyclonal AntibodyGelatinase B; inflammatory cell-derived; degrades basement membrane collagen.
Collagenases
Anti-MMP-1 Rabbit Polyclonal AntibodyInterstitial collagenase; cleaves fibrillar collagens I, II, III.
Anti-MMP-8 Rabbit Polyclonal AntibodyNeutrophil collagenase; degrades interstitial collagens in inflammation.
Anti-MMP-13 Rabbit Polyclonal AntibodyCollagenase-3; broad substrate range; implicated in bone metastasis.
Stromelysins
Anti-MMP-3 Rabbit Polyclonal AntibodyStromelysin-1; activates other pro-MMPs; degrades ECM and pro-cytokines.
Anti-MMP-10 Rabbit Polyclonal AntibodyStromelysin-2; cleaves collagens III, IV, V and proteoglycans.
Anti-MMP-11 Rabbit Polyclonal AntibodyStromelysin-3; stromal expression in breast cancer; unclear substrates.
Matrilysins
Anti-MMP-7 Rabbit Polyclonal AntibodyMatrilysin-1; broad substrate range; epithelial expression in GI cancers.
Anti-MMP-26 Rabbit Polyclonal AntibodyMatrilysin-2; endometrial expression; cleaves fibronectin and gelatin.
Membrane-Type MMPs (MT-MMPs)
Anti-MMP-14 Rabbit Polyclonal AntibodyMT1-MMP; invadopodia localization; activates pro-MMP-2; transmembrane.
Anti-MMP-15 Rabbit Polyclonal AntibodyMT2-MMP; transmembrane; activates pro-MMP-2; leukocyte expression.
Anti-MMP-16 Rabbit Polyclonal AntibodyMT3-MMP; transmembrane; activates pro-MMP-2; collagenolytic activity.
Anti-MMP-17 Rabbit Polyclonal AntibodyMT4-MMP; GPI-anchored; leukocyte expression; substrate unclear.
Anti-MMP-24 Rabbit Polyclonal Antibody (human)MT5-MMP; brain-enriched; glioma invasion; transmembrane.
Anti-MMP-24 Rabbit Polyclonal Antibody (mouse)MT5-MMP mouse isoform; nervous system expression.
Anti-MMP-25 Rabbit Polyclonal AntibodyMT6-MMP; GPI-anchored; leukocyte expression; gelatinolytic.
Other MMPs
Anti-MMP-12 Rabbit Polyclonal AntibodyMacrophage metalloelastase; degrades elastin; macrophage-derived.
Anti-MMP-18 Rabbit Polyclonal AntibodyCollagenase-4; Xenopus ortholog; limited mammalian data.
Anti-MMP-19 Rabbit Polyclonal AntibodyExpressed in liver, prostate; cleaves tenascin, aggrecan, gelatin.
Anti-MMP-20 Rabbit Polyclonal AntibodyEnamelysin; enamel matrix degradation; odontogenic tumors.
Anti-MMP-21 Rabbit Polyclonal AntibodyCleaves gelatin; macrophage and fibroblast expression.
Anti-MMP-21 Rabbit Polyclonal Antibody (alternate epitope)Human MMP-21 detection; alternative immunogen.
Anti-MMP-23 Rabbit Polyclonal AntibodyTransmembrane; lacks hemopexin domain; ovary, prostate expression.
Anti-MMP-27 Rabbit Polyclonal AntibodyMinimal domain MMP; B lymphocyte expression; substrate unclear.
Anti-MMP-27 Rabbit Polyclonal Antibody (C-terminal)MMP-27 C-terminal epitope; alternative detection.
Anti-MMP-28 Rabbit Polyclonal AntibodyEpilysin; keratinocyte expression; cleaves casein.
TIMPs (Tissue Inhibitors of Metalloproteinases)
Anti-TIMP-1 Rabbit Polyclonal AntibodyInhibits most MMPs; preferentially MMP-9; secreted, soluble.
Anti-TIMP-2 Rabbit Polyclonal AntibodyRegulates pro-MMP-2 activation; forms complex with MT1-MMP.
Anti-TIMP-3 Rabbit Polyclonal AntibodyECM-bound; inhibits MMPs and ADAMs; frequently silenced in cancer.
Anti-TIMP-4 Rabbit Polyclonal AntibodyHeart and brain expression; inhibits MMP-2, MMP-9, MT1-MMP.
ADAM Proteases
Anti-ADAM-9 Rabbit Polyclonal AntibodyMeltrin-γ; sheds HB-EGF, KIT ligand; broad tissue expression.
Anti-ADAM-10 Rabbit Polyclonal AntibodyKuzbanian; principal Notch sheddase; cleaves E-cadherin, APP.
Anti-ADAM-12 Rabbit Polyclonal AntibodyMeltrin-α; muscle, placenta; cleaves IGFBP-3 and -5.
Anti-ADAM-15 Rabbit Polyclonal AntibodyMetargidin; endothelial and osteoblast expression; integrin binding.
Anti-ADAM-17 Rabbit Polyclonal AntibodyTACE; cleaves TNF-α, EGFR ligands, Notch; therapeutic target.
Anti-ADAM-28 Rabbit Polyclonal AntibodyLymphocyte expression; cleaves von Willebrand factor, IGFBP-3.
ADAMTS Proteases
Anti-ADAMTS-1 Rabbit Polyclonal AntibodyCleaves versican, aggrecan; angiogenesis inhibitor; ECM remodeling.
Anti-ADAMTS-4 Rabbit Polyclonal AntibodyAggrecanase-1; cartilage degradation; osteoarthritis and tumor stroma.
Anti-ADAMTS-5 Rabbit Polyclonal AntibodyAggrecanase-2; principal aggrecanase; cartilage and tendon.
Anti-ADAMTS-7 Rabbit Polyclonal AntibodyCleaves COMP; vascular smooth muscle; atherosclerosis implicated.
Anti-ADAMTS-13 Rabbit Polyclonal AntibodyCleaves von Willebrand factor multimers; TTP deficiency; platelet biology.
Related Metalloproteases & Regulators
Anti-BMP-1 Rabbit Polyclonal AntibodyProcollagen C-proteinase; activates TGF-β, BMPs; astacin family.
Anti-Pappalysin-1 Rabbit Polyclonal AntibodyPAPP-A; pregnancy-associated; cleaves IGFBP-4; cancer implicated.
Anti-Pappalysin-2 Rabbit Polyclonal AntibodyPAPP-A2; cleaves IGFBP-5; placenta and bone.
Anti-RECK Rabbit Polyclonal AntibodyMembrane-anchored MMP inhibitor; suppresses MMP-2, MMP-9, MT1-MMP.